Picture EBD Group ChinaBio Partnerting Forum 2021 651x80
Organisation › Details

Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX)

Calliditas Therapeutics is a specialty pharmaceutical company focused on developing high value medical products for patients with significant unmet medical needs in niche indications. Calliditas Therapeutics is focused on the development and commercialization of its lead product candidate, Nefecon, which has successfully completed a Phase 2b clinical study as a potential new treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Backed by a strong investor base with a clear long-term vision and a track record of bringing products to the market, Calliditas Therapeutics aims to take Nefecon through a global Phase 3 study to commercialization. In addition, the company has identified other potential uses of Nefecon in niche indications, and will investigate the development of these to provide new treatments for patients with unmet medical needs. *


Period Start 2017-11-15 renamed
  Group Calliditas Therapeutics (Group)
  Predecessor Pharmalink AB
Products Industry pharmaceutical
  Industry 2 Nefecon®
Persons Person Aguiar-Lucander, Renée (Pharmalink AB 201708 CEO)
  Person 2 Johansson, Fredrik (Pharmalink AB 201708– CFO before Birdstep Technology/Techstep ASA)
Region Region Stockholm
  Country Sweden
  Street 1 Kungsbron
  City 11122 Stockholm
  Tel +46-8-411-3005
    Address record changed: 2020-12-02
Basic data Employees B: 11 to 50 (2020-03-31)
  Currency SEK
  Annual sales 184,829,000 (net sales, consolidated (2019) 2019-12-31)
  Profit -32,578,000 (2019-12-31)
  Cash 753,540,000 (2019-12-31)
    * Document for �About Section�: Calliditas Therapeutics AB. (11/15/17). "Press Release: Pharmalink Is Renamed Calliditas Therapeutics".
Record changed: 2020-09-27


Picture ConsulTech GmbH RnD Credit Germany 650x80px

More documents for Calliditas Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group ChinaBio Partnerting Forum 2021 651x80

» top